{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IVT+Aflibercept&page=3", "query": { "intervention": "IVT Aflibercept", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 65, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IVT+Aflibercept&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IVT+Aflibercept&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-02T03:40:49.265Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03386474", "title": "Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neovascular Age-related Macular Degeneration" ], "interventions": [ { "name": "Brolucizumab 6 mg", "type": "DRUG" }, { "name": "Aflibercept 2 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 151, "start_date": "2018-01-15", "completion_date": "2018-09-06", "has_results": true, "last_update_posted_date": "2021-01-05", "last_synced_at": "2026-10-02T03:40:49.265Z", "location_count": 63, "location_summary": "Peoria, Arizona • Phoenix, Arizona • Arcadia, California + 56 more", "locations": [ { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Arcadia", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03386474" }, { "nct_id": "NCT07482176", "title": "Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neovascular Age-Related Macular Degeneration (nAMD)", "Wet AMD" ], "interventions": [ { "name": "Ixo-vec", "type": "GENETIC" }, { "name": "Aflibercept", "type": "DRUG" } ], "intervention_types": [ "GENETIC", "DRUG" ], "sponsor": "Adverum Biotechnologies, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 534, "start_date": "2026-03-16", "completion_date": "2031-10-20", "has_results": false, "last_update_posted_date": "2026-09-24", "last_synced_at": "2026-10-02T03:40:49.265Z", "location_count": 79, "location_summary": "Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 65 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT07482176" }, { "nct_id": "NCT06942520", "title": "Phase 2 Trial of RGX-314 in Adults With Center Involved - Diabetic Macular Edema (CI - DME)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetic Macular Edema" ], "interventions": [ { "name": "RGX-314 Dose 1", "type": "GENETIC" }, { "name": "RGX-314 Dose 2", "type": "GENETIC" }, { "name": "Aflibercept (2.0 mg)", "type": "BIOLOGICAL" } ], "intervention_types": [ "GENETIC", "BIOLOGICAL" ], "sponsor": "Sierra Eye Associates", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "25 Years", "maximum_age": "89 Years", "sex": "ALL", "summary": "25 Years to 89 Years" }, "enrollment_count": 18, "start_date": "2025-03-18", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2025-04-24", "last_synced_at": "2026-10-02T03:40:49.265Z", "location_count": 1, "location_summary": "Reno, Nevada", "locations": [ { "city": "Reno", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT06942520" }, { "nct_id": "NCT04740905", "title": "A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Macular Edema", "Branch Retinal Vein Occlusion" ], "interventions": [ { "name": "Faricimab", "type": "DRUG" }, { "name": "Aflibercept", "type": "DRUG" }, { "name": "Sham Procedure", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 553, "start_date": "2021-03-02", "completion_date": "2023-06-12", "has_results": true, "last_update_posted_date": "2024-08-06", "last_synced_at": "2026-10-02T03:40:49.265Z", "location_count": 39, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Campbell, California + 36 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Campbell", "state": "California" }, { "city": "Encino", "state": "California" }, { "city": "Pasadena", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04740905" }, { "nct_id": "NCT03710564", "title": "Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Age-Related Macular Degeneration" ], "interventions": [ { "name": "Brolucizumab", "type": "BIOLOGICAL" }, { "name": "Aflibercept", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 535, "start_date": "2018-10-30", "completion_date": "2021-07-01", "has_results": true, "last_update_posted_date": "2023-01-30", "last_synced_at": "2026-10-02T03:40:49.265Z", "location_count": 60, "location_summary": "Phoenix, Arizona • Beverly Hills, California • Huntington Beach, California + 51 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Huntington Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03710564" }, { "nct_id": "NCT05930561", "title": "4D-150 in Patients With Diabetic Macular Edema", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetic Macular Edema", "Diabetic Retinopathy" ], "interventions": [ { "name": "4D-150 IVT", "type": "BIOLOGICAL" }, { "name": "Aflibercept IVT", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "4D Molecular Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 72, "start_date": "2023-08-09", "completion_date": "2029-02-28", "has_results": false, "last_update_posted_date": "2026-08-21", "last_synced_at": "2026-10-02T03:40:49.265Z", "location_count": 5, "location_summary": "Hagerstown, Maryland • Eugene, Oregon • Erie, Pennsylvania + 2 more", "locations": [ { "city": "Hagerstown", "state": "Maryland" }, { "city": "Eugene", "state": "Oregon" }, { "city": "Erie", "state": "Pennsylvania" }, { "city": "Austin", "state": "Texas" }, { "city": "Lynchburg", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05930561" }, { "nct_id": "NCT07064759", "title": "Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neovascular Age-Related Macular Degeneration (nAMD)" ], "interventions": [ { "name": "4D-150 IVT (3E10 vg/eye)", "type": "BIOLOGICAL" }, { "name": "EYLEA® (aflibercept) Injection 2 mg (0.05mL)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "4D Molecular Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 480, "start_date": "2025-07-22", "completion_date": "2029-02", "has_results": false, "last_update_posted_date": "2026-04-16", "last_synced_at": "2026-10-02T03:40:49.265Z", "location_count": 54, "location_summary": "Scottsdale, Arizona • Sun City, Arizona • Tucson, Arizona + 49 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Campbell", "state": "California" }, { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07064759" }, { "nct_id": "NCT05850520", "title": "A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Macular Edema Secondary to Retinal Vein Occlusion" ], "interventions": [ { "name": "Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose", "type": "DRUG" }, { "name": "Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg", "type": "DRUG" }, { "name": "Sham", "type": "DRUG" }, { "name": "Fluorescein", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 892, "start_date": "2023-05-15", "completion_date": "2025-05-27", "has_results": true, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-10-02T03:40:49.265Z", "location_count": 53, "location_summary": "Fullerton, California • Long Beach, California • Mountain View, California + 48 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Mountain View", "state": "California" }, { "city": "Palm Springs", "state": "California" }, { "city": "Pasadena", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05850520" }, { "nct_id": "NCT06817343", "title": "A Long-term Follow up Study of EXG102-031 in Patients With wAMD (Everest LTFU)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neovascular Age-Related Macular Degeneration (nAMD)", "Neovascular (Wet) Age-related Macular Degeneration (AMD)" ], "interventions": [ { "name": "Aflibercept (2.0 mg)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Exegenesis Bio", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 12, "start_date": "2024-09-10", "completion_date": "2029-02", "has_results": false, "last_update_posted_date": "2026-04-08", "last_synced_at": "2026-10-02T03:40:49.265Z", "location_count": 2, "location_summary": "Reno, Nevada • Erie, Pennsylvania", "locations": [ { "city": "Reno", "state": "Nevada" }, { "city": "Erie", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06817343" }, { "nct_id": "NCT00943072", "title": "Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Macular Edema Secondary to Central Retinal Vein Occlusion" ], "interventions": [ { "name": "VEGF Trap-Eye 2.0mg", "type": "BIOLOGICAL" }, { "name": "Sham", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 189, "start_date": "2009-07", "completion_date": "2012-04", "has_results": true, "last_update_posted_date": "2013-05-27", "last_synced_at": "2026-10-02T03:40:49.265Z", "location_count": 46, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 41 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Arcadia", "state": "California" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00943072" } ] }